Omeros Corporation expects to complete a $31.3 million repurchase of $16.0 million in aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 on July 6, 2026. Additionally, the Company entered into new agreements on July 2, 2026, to repurchase up to $14.5 million in aggregate principal amount of additional Notes for a total purchase price of up to $31.0 million, expected to close between July 20 and July 30, 2026. Omeros Corporation is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for ocular and inflammatory diseases.
